EMAIL THIS PAGE TO A FRIEND

American journal of physiology. Lung cellular and molecular physiology

Angiotensin II type 2 receptor ligand PD123319 attenuates hyperoxia-induced lung and heart injury at a low dose in newborn rats.


PMID 24951776

Abstract

Intervening in angiotensin (Ang)-II type 2 receptor (AT2) signaling may have therapeutic potential for bronchopulmonary dysplasia (BPD) by attenuating lung inflammation and preventing arterial hypertension (PAH)-induced right ventricular hypertrophy (RVH). We first investigated the role of AT2 inhibition with PD123319 (0.5 and 2 mg·kg(-1)·day(-1)) on the beneficial effect of AT2 agonist LP2-3 (5 μg/kg twice a day) on RVH in newborn rats with hyperoxia-induced BPD. Next we determined the cardiopulmonary effects of PD123319 (0.1 mg·kg(-1)·day(-1)) in two models: early treatment during continuous exposure to hyperoxia for 10 days and late treatment starting on day 6 in rat pups exposed postnatally to hyperoxia for 9 days, followed by a 9-day recovery period in room air. Parameters investigated included lung and heart histopathology, fibrin deposition, vascular leakage, and differential mRNA expression. Ten days of coadministration of LP2-3 and PD123319 abolished the beneficial effects of LP2-3 on RVH in experimental BPD. In the early treatment model PD123319 attenuated cardiopulmonary injury by reducing alveolar septal thickness, pulmonary influx of inflammatory cells, including macrophages and neutrophils, medial wall thickness of small arterioles, and extravascular collagen III deposition, and by preventing RVH. In the late treatment model PD123319 diminished PAH and RVH, demonstrating that PAH is reversible in the neonatal period. At high concentrations PD123319 blocks the beneficial effects of the AT2-agonist LP2-3 on RVH. At low concentrations PD123319 attenuates cardiopulmonary injury by reducing pulmonary inflammation and fibrosis and preventing PAH-induced RVH but does not affect alveolar and vascular development in newborn rats with experimental BPD.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB2502167
Anti-MPO antibody produced in goat, affinity isolated antibody, buffered aqueous solution
HPA021147
Anti-MPO antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
F3520
Anti-von Willebrand Factor antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
SAB1406590
Anti-VWF antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA001815
Anti-VWF antibody produced in rabbit, Ab1, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
HPA002082
Anti-VWF antibody produced in rabbit, Ab2, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1408640
Anti-VWF antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB1409321
Monoclonal Anti-MPO antibody produced in mouse, clone 3E11, purified immunoglobulin, buffered aqueous solution
AMAB90928
Monoclonal Anti-VWF antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1950, purified immunoglobulin, buffered aqueous glycerol solution
AMAB90931
Monoclonal Anti-VWF antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1957, purified immunoglobulin, buffered aqueous glycerol solution
SAB1402960
Monoclonal Anti-VWF antibody produced in mouse, clone 1A11, purified immunoglobulin, buffered aqueous solution